Shares of arGEN-X BV (NASDAQ:ARGX) have been assigned an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price target of $91.67 for the company and are expecting that the company will post ($0.51) EPS for the current quarter, according to Zacks. Zacks has also given arGEN-X BV an industry rank of 183 out of 265 based on the ratings given to related companies.
Several research firms have recently issued reports on ARGX. JMP Securities upped their price objective on arGEN-X BV from $74.00 to $87.00 and gave the stock an “outperform” rating in a research report on Monday, January 29th. Zacks Investment Research cut arGEN-X BV from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. SunTrust Banks initiated coverage on arGEN-X BV in a report on Sunday. They issued a “buy” rating and a $125.00 target price for the company. Finally, Piper Jaffray boosted their target price on arGEN-X BV to $100.00 and gave the company an “overweight” rating in a report on Tuesday, December 19th.
A hedge fund recently raised its stake in arGEN-X BV stock. Alyeska Investment Group L.P. increased its position in arGEN-X BV (NASDAQ:ARGX) by 1.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 121,313 shares of the company’s stock after purchasing an additional 2,167 shares during the period. Alyeska Investment Group L.P. owned 0.45% of arGEN-X BV worth $2,743,000 at the end of the most recent quarter. Institutional investors own 44.94% of the company’s stock.
Shares of NASDAQ:ARGX traded up $5.07 on Wednesday, hitting $79.91. 60,342 shares of the company’s stock were exchanged, compared to its average volume of 190,680. arGEN-X BV has a 1-year low of $17.33 and a 1-year high of $87.00.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/09/analysts-expect-argen-x-bv-argx-to-post-0-51-earnings-per-share.html.
About arGEN-X BV
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Get a free copy of the Zacks research report on arGEN-X BV (ARGX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for arGEN-X BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for arGEN-X BV and related companies with MarketBeat.com's FREE daily email newsletter.